MassIVEapplication/xmlftp://massive-ftp.ucsd.edu/v07/MSV000094231/primary200OKProteomicsDing QiangQ Exactive HF-XTrichuris Sp. Ex Homo Sapiens Jp-2011 (ncbitaxon:1035824)https://massive.ucsd.edu/ProteoSAFe/dataset.jsp?task=d6d53355d0d54dddb603119b2104375ddingqiang@njmu.edu.cnNanjing Medical UniversityMassIVE11noprimary breast cancer, DmelCG40411, malignant tumor of the breast, LD21673.3prime, Neoplasms, mammary neoplasm, Mammary Cancers, Human Mammary Neoplasms, BEST:LD21673, Tumor, Human, Adprt1, complementation Group 1, Breast Malignant Tumor, CG40411, "neoplasm of breast (disorder)" EXACT [SNOMEDCT_2005_07_31:126926005], Breast Tumor, Alleviating interaction, "mammary tumor" EXACT [CSP2005:2016-0671], breast tumor, cancer of the breast, C80510, ADPRT, CG17696, BC, Mammary Neoplasms, malignant neoplasm of breast, Human Mammary, Fanconi Anemia, Adprp, ARTD1, ADPRT1, Adprt, Mammary Neoplasm, AI893648, Mammary Carcinoma, Human Mammary Carcinomas, inhibiteur, complementation group I, adprt1, suppressive genetic interaction (sensu inequality), Cancer of the Breast, FANCI, inhibidor, cancer of breast, Malignant Tumor of Breast, Mammary, Mammary Cancer, fanci, parp-1, Breast, mammary cancer, mammary tumor, Tumors, Cancer, poly(ADP-ribose) polymerase 1, inhibitors, F16D14.16, Breast Carcinoma, Human Mammary Neoplasm, Carcinoma, Fanconi anemia, CG13745, Breast Carcinomas, "breast neoplasm" EXACT [MTH:120], KIAA1794, pADPRT-1, inhibitor, DmelCG13745, "breast tumor" EXACT [NCI2004_11_17:C2910], F16D14_16, ATPARP1, DFNA13, Breast Malignant Neoplasm, PARP1, Mammary Carcinomas, sPARP-1, STL3, Neoplasm, Human Mammary Carcinoma, NOS, Malignant Neoplasm of Breast, antagonists, Carcinomas, Breast Neoplasm, PARP, Cancers, Breast Malignant Neoplasms., "mammary neoplasm" RELATED [], parp, CG17685, DFNB53, CG17718, Parp-1, padprt-1, ppol, antagonists and inhibitors, breast cancer, FBCG2, ADPRT 1, PARP-1, Breast Tumors, Breast Cancer, D.PARP, Breast Malignant Tumors, HKE5, Cancer of Breast, dPARP, Dm.pARTa, PPOL, 5830444G22Rik, cancer, breastIgG Antibody, Co-Immunoprecipitations, Fanconi anemia, CG13745, determination, KIAA1794, Immunoglobulin, DmelCG13745, mammary gland carcinoma cell, B-cell receptor complex, Spectrum Analyses, antibodies, IgG1 antibody, Spectrum Analysis, IgG4 antibody, Co Immunoprecipitation, Spectroscopy, complementation Group 1, antibody, Antibody, MS, BCR complex, IgG3, IgG4, IgG1, Gamma Globulin, IgG2, chemical analysis, Immune Precipitations, Mass, Analysis, immunoglobulin complex, Immune Precipitation, Mass Spectrum Analyses, mammary carcinoma cell, mammary adenocarcinoma cell, Mass Spectroscopy, Mass Spectrum Analysis, opsonin activity, IgG3 antibody, Mass Spectrum, IgG2a antibody, IgG antibody, ZR-75-1., Fanconi Anemia, IgG, Analyses, Immunoglobulin GT, IgG(T), membrane bound, mammary cancer cell, Co-Immunoprecipitation, Polyglobin, Precipitation, Spectrometry, breast epithelial cancer cell, complementation group I, breast carcinoma cell, breast adenocarcinoma cell, FANCI, immunoglobulin, breast tumor cell, Immune, B cell receptor accessory molecule complex, IgG2 antibody, IgG2c antibody, IgG2A, IgG2B, GT, B lymphocyte receptor complex, 7S Gamma Globulin, B cell receptor activity, fanci, Allerglobuline, mammary tumor cell, IgG2b antibody, assay, Precipitations, B-lymphocyte receptor complex, 7SfalseEmerging combination strategy: FANCI suppression induces PARP1 redistribution to enhance efficacy of PARP inhibitors in breast cancer The data of co-immunoprecipitation (co-IP) followed by mass spectrometry (MS) analysis using FANCI antibody and non-specific IgG antibody in breast cancer cell lines SUM-1315 and ZR-75-1.Mon Mar 04 02:37:00 GMT 2024MSV000094231